AKT1 and pachyonychia congenita: Mechanistically, we have demonstrated that the combination therapy affects the lipid content in tumor cells by causing a decrease in MUFA that affects the activation of the PI3K/AKT pathway, a major oncogenic pathway in PC, resulting in diminished cell proliferation.